Long-term-Vitrakvi-larotrectinib-confirm-sustained-clinical-benefit-greater-years-patients-TRK
Larotrectinib achieved 75% (95% CI 68-81) overall response rate (ORR) and median duration of response (DoR) of 49.3 months (95% CI 27.3-not estimable [NE]) in expanded integrated dataset of 206 evaluable adults and children with TRK fusion cancer, which occurs when an NTRK gene fuses with another unrelated gene, across 21 different tumor types and regardless of age (range: 0.1-84 years) with longer follow-up at a median follow-up of 22.3 months / In tumor-specific analyses, larotrectinib demonstrated rapid and durable responses, and long disease control, among patients with lung and primary central nervous system (CNS) TRK...
Source: Bayer Company News - May 19, 2021 Category: Pharmaceuticals Source Type: news
Finerenone-potential-reduce-onset-atrial-fibrillation-flutter-patients-chronic-kidney-disease-2
A prespecified exploratory analysis of the FIDELIO-DKD study demonstrates that finerenone may significantly reduce the risk of new onset atrial fibrillation or flutter (AFF) in patients with CKD and T2D versus placebo when added to standard of care / This analysis also concluded that finerenone reduced the risk of kidney or cardiovascular events with no significant difference in the effect of finerenone between patients with and without history of AFF at baseline / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor (MR) a...
Source: Bayer Company News - May 17, 2021 Category: Pharmaceuticals Source Type: news
Bayer-successful-start-to-2021
Good operational performance – sales and earnings negatively impacted by currency of 938 million euros and 337 million euros / Group sales up by 2.8 percent (Fx & portfolio adj.) to 12.328 billion euros / EBITDA before special items down 6.2 percent to 4.118 billion euros due to currency / Strong sales growth at Crop Science (Fx & portfolio adj.) in improved market environment / Sales at Pharmaceuticals (Fx & portfolio adj.) at prior-year level / Consumer Health ahead of competition with continuous good performance / Net income advances by 40.3 percent to 2.089 billion euros / Core earnings per share decline by 3.0 p...
Source: Bayer Company News - May 12, 2021 Category: Pharmaceuticals Source Type: news
Bayers-finerenone-meets-primary-endpoint-Phase-III-FIGARO-DKD-cardiovascular-outcomes-study-patients
Finerenone significantly reduced the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care / Following the FIDELIO-DKD study, FIGARO-DKD is the second positive Phase III study within the finerenone study program in chronic kidney disease (CKD) and type 2 diabetes (T2D) to meet its primary endpoint / Patients with CKD and T2D are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroid...
Source: Bayer Company News - May 10, 2021 Category: Pharmaceuticals Source Type: news
Were-optimistic-for-the-future
Stable operational development in fiscal 2020 despite the COVID-19 pandemic / Dividend of 2.00 euros per share proposed / Early indications of a successful start to 2021 / Board of Management regards Bayer as better positioned than almost any other company to realize the long-term innovation potential of the bio-revolution / Stockholders to elect two new Supervisory Board members (Source: Bayer Company News)
Source: Bayer Company News - April 27, 2021 Category: Pharmaceuticals Source Type: news
Combination-copanlisib-rituximab-significantly-increases-progression-free-survival-patients-relapsed
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with pre...
Source: Bayer Company News - April 10, 2021 Category: Pharmaceuticals Source Type: news
Bayer-receives-approval-for-Vitrakvi-in-Japan
Precision oncology treatment Vitrakvi™ (larotrectinib) approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors / In clinical studies, larotrectinib demonstrated high response rates and durable responses in adults and children with TRK fusion cancer, including responses and a high disease control rate in primary central nervous system (CNS) tumors / The Japanese marketing authorization of Vitrakvi follows the approval of the expanded use of FoundationOne®CDx, a comprehensive genomic profiling (CGP) test, in Japan for use as a companion diagnostic (CDx) to identify patients with TRK fusio...
Source: Bayer Company News - March 23, 2021 Category: Pharmaceuticals Source Type: news
Bayer-to-further-strengthen-expertise-and-international-profile-of-its-Supervisory-Board
Fei-Fei Li and Alberto Weisser proposed as successors to Johanna Faber and Prof. Dr. Wolfgang Plischke / Supervisory Board compensation to be adjusted (Source: Bayer Company News)
Source: Bayer Company News - March 12, 2021 Category: Pharmaceuticals Source Type: news
Bayer-expects-dynamic-growth-higher-profitability-coming-years-accelerating-transformation
Crop Science: Clear innovation leader in its industry – expected sales and earnings growth above market / Pharmaceuticals: Further growth planned through 2023, new products expected to largely offset the effect of patent expirations – position in cell and gene therapy to be expanded / Consumer Health: Moved from industry underperformer to outperformer – further sales and earnings improvements planned / Core earnings per share anticipated to increase to 7.00 to 7.50 euros by 2024 / Further operational improvements to raise free cash flow to 5 billion euros by 2024 / Bayer in an excellent position to benefi...
Source: Bayer Company News - March 10, 2021 Category: Pharmaceuticals Source Type: news
Bayer-delivers-robust-performance-despite-pandemic-foundation-laid-for-future-growth
Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & portfolio adj. plus 0.6 percent) / EBITDA before special items level with prior year at 11.461 billion euros (minus 0.1 percent) – currency effects offset by stringent cost management / Crop Science and Pharmaceuticals report stable operational business, Consumer Health sees strong growth / Core earnings per share at 6.39 euros (plus 0.2 percent) / Earnings per share at minus 10.68 euros (2019: plus 4.17 euros), impacted by litigation provisions and impairments / Net financial debt improves by 11.8 percent to 30.04...
Source: Bayer Company News - February 25, 2021 Category: Pharmaceuticals Source Type: news
Bayer-Divest-Environmental-Science-Professional-Business-Further-Strengthen-Leadership-Team-Crop
(Source: Bayer Company News)
Source: Bayer Company News - February 24, 2021 Category: Pharmaceuticals Source Type: news
Bayer-submits-finerenone-marketing-authorization-China-treatment-chronic-kidney-disease-2-diabetes
(Source: Bayer Company News)
Source: Bayer Company News - February 9, 2021 Category: Pharmaceuticals Source Type: news
New-presented-ASCO-GU-Cancers-Symposium-robustness-overall-survival-benefit-favorable-safety-profile
New analyses from the Phase III ARAMIS trial further strengthen the overall survival benefit and favorable safety profile of darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Additional data from darolutamide and radium-223 dichloride (Xofigo™) trials demonstrate Bayer’s continued commitment to ongoing prostate cancer research to bring meaningful benefit to the lives of men across different stages of the disease / Expert-led and patient perspectives as well as additional prostate cancer educational resources for media can be found on Bayer’s ASCO GU Vi...
Source: Bayer Company News - February 8, 2021 Category: Pharmaceuticals Source Type: news
Bayer-and-Orion-expand-development-program-for-darolutamide-in-prostate-cancer
Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the novel androgen-receptor antagonist in combination with standard androgen deprivation therapy / Start of patient enrollment expected by the end of Q1 2021 / Study adds to the robust development program for NUBEQA, exploring an opportunity to help even more patients with prostate cancer (Source: Bayer Company News)
Source: Bayer Company News - February 8, 2021 Category: Pharmaceuticals Source Type: news
Bayer-receives-approval-Nubeqa-China-treatment-non-metastatic-castration-resistant-prostate-cancer
(Source: Bayer Company News)
Source: Bayer Company News - February 3, 2021 Category: Pharmaceuticals Source Type: news
